CCDM Clinical Trial Design 5 — Questions and Answers
Question 1: In a registry-based randomized clinical trial (RRCT), what is the primary source of outcome data?
- Dedicated paper case report forms collected by site monitors
- Existing patient registry databases integrated with trial randomization (Correct answer)
- Laboratory specimens collected at study-specific time points
- Patient-reported outcome diaries submitted by mail
Correct answer: Existing patient registry databases integrated with trial randomization
RRCTs leverage existing national or disease registries to collect outcome data, reducing costs and enabling pragmatic, large-scale evidence generation.
Question 2: A 'platform trial' differs from a standard multi-arm trial in that it:
- Tests only one treatment arm against placebo
- Allows new treatment arms to be added or dropped over time under a master protocol (Correct answer)
- Requires separate IRB approval for each new treatment arm added
- Is limited to rare disease populations
Correct answer: Allows new treatment arms to be added or dropped over time under a master protocol
Platform trials operate under a single master protocol and infrastructure, allowing flexible addition or removal of treatment arms based on pre-specified decision rules.
Question 3: Which of the following endpoints would be classified as a 'composite endpoint'?
- Overall survival measured from randomization to death from any cause
- Time to first occurrence of myocardial infarction, stroke, or cardiovascular death (Correct answer)
- Change from baseline in LDL cholesterol at 12 weeks
- Physician global assessment score at week 24
Correct answer: Time to first occurrence of myocardial infarction, stroke, or cardiovascular death
Composite endpoints combine multiple individual events into a single endpoint, which increases event rates and reduces required sample size, but can complicate interpretation.
Question 4: In clinical trial design, 'multiplicity' refers to:
- Enrolling patients at multiple international sites
- The inflation of Type I error risk when multiple statistical tests or endpoints are evaluated (Correct answer)
- The use of multiple consent forms for complex procedures
- Testing the same drug in multiple disease indications simultaneously
Correct answer: The inflation of Type I error risk when multiple statistical tests or endpoints are evaluated
Testing multiple hypotheses increases the chance of obtaining at least one false-positive result by chance, requiring pre-specified adjustment strategies like Bonferroni correction.
Question 5: Which ICH guideline specifically provides guidance on statistical principles for clinical trials?
- ICH E6 (R2)
- ICH E9 (R1) (Correct answer)
- ICH E3
- ICH Q10
Correct answer: ICH E9 (R1)
ICH E9 (R1) provides guidance on statistical principles for clinical trials, and its addendum (R1) introduced the estimand framework for defining trial objectives precisely.
Question 6: A 'hybrid decentralized clinical trial' (DCT) design incorporates which key feature compared to a fully site-based trial?
- All visits are conducted exclusively at the clinical site with no remote elements
- Some or all trial activities are conducted remotely at the patient's home or local facility (Correct answer)
- Participants are enrolled only from a single geographic region
- Data collection is limited to electronic patient-reported outcomes only
Correct answer: Some or all trial activities are conducted remotely at the patient's home or local facility
Hybrid DCTs blend traditional site visits with remote activities (telemedicine, home nursing, wearables), expanding access and potentially improving recruitment and retention.
Question 7: The estimand framework introduced in ICH E9 (R1) requires specifying which of the following components for each trial objective?
- Sample size, alpha level, power, and analysis population
- Population, treatment, variable (endpoint), population-level summary, and intercurrent event handling strategy (Correct answer)
- Randomization method, blinding level, control type, and stratification factors
- Primary, secondary, exploratory, and safety endpoints with their hierarchy
Correct answer: Population, treatment, variable (endpoint), population-level summary, and intercurrent event handling strategy
The estimand framework requires precisely defining what is being estimated by specifying: the target population, the interventions, the endpoint, how intercurrent events are handled, and the population-level summary statistic.
CCDM Clinical Trial Design 5
In a registry-based randomized clinical trial (RRCT), what is the primary source of outcome data?